Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
3RYQJVxDF5JqWdCF
